Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Chiesi Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America Massachusetts Austria

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.This agreement expands Chiesi's comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date.Haisco Pharmaceutical will receive an upfront payment and future milestone payments, including royalties on product sales.View original content:https://www.prnewswire.com/news-releases/chiesi-group-signed-a-license-agreement-with-haisco-pharmaceutical-to-develop-manufacture-and-commercialise-a-novel-reversible-dipeptidyl-peptidase-1-inhibitor-for-bronchiectasis-301992409.html